Chemotherapy of patients with colorectal carcinoma;Medicamenteuze behandeling van patiënten met colorectumcarcinoom

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 26, 2005, Pages 1441-1447

  Punt, C J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLACEBO; TEGAFUR; UFT; URACIL; VASCULOTROPIN;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PROGNOSIS; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; INCIDENCE; LEUCOVORIN; NEOPLASM STAGING; NETHERLANDS; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PROGNOSIS;

EID: 21244436374     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Signaleringscommissie Kanker van KWF Kankerbestrijding. Kanker in Nederland, trends, prognoses en implicaties voor zorgvraag. Amsterdam: Nederlandse Kankerbestrijding/Koningin Wilhelmina Fonds; 2004.
2. Chirieac L, Suehiro Y, Niemisto A, Shmulevich I, Lunagomez S, Morris J, et al. Size and number of examined lymph nodes impacts outcome in patients with stage II colorectal cancer [abstract 3507]. Proc Am Soc Clin Oncol 2004;23:2475.
3. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons jr RJ, Erlichman C, Shepherd LE, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300.
4. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;354:638-46.
5. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531-5.
6. Sargent DJ, Wiend S, Benedetti J, Labianca R, Haller DG, Shepherd LE, et al. Disease-free survival vs. overall survival as a primary end-point for adjuvant colon cancer studies: individual patient data from 12.915 patients on 15 randomised trials [abstract 3502]. Proc Am Soc Clin Oncol 2004;23:245S.
7. Miller LL, Elfring GL, Gruia G, Hirawat S, Douillard JY, Saltz LB. A case for time to progression (TTP) as the primary efficacy endpoint in 1st-line metastatic colorectal cancer therapy: correlation of TTP and overall survival [abstract 3503]. Proc Am Soc Clin Oncol 2004;23: 245S.
8. Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 2004;15:545-9.
9. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356-63.
10. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-55.
11. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13: 2936-43.
12. Taal BG, Tinteren H van, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. NACCP Group. Br J Cancer 2001;85:1437-43.
13. Gray RG, Barnwell J, Hills R, McConkey C, Willimas N, Kerr D. QUASAR: a randomized study of adjuvant chemotherapy vs observation including 3238 colorectal cancer patients [abstract 3501]. Proc Am Soc Clin Oncol 2004;23:245S.
14. Cassidy I, Scheithauer W, McKendrick J, Kröning H, Nowacki MP, Seitz JF, et al. Capecitabine vs bolus 5FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial [abstract 3509]. Proc Am Soc Clin Oncol 2004; 23:247S.
15. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP protocol C-06 [abstract 3508]. Proc Am Soc Clin Oncol 2004;23:247S.
16. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan plus fluorouracil/leucovorin versus fluorouracil/ leucovorin alone in stage III colon cancer (intergroup trial CALGB C89803) [abstract 3500]. Proc Am Soc Clin Oncol 2004;23:245S.
17. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
18. Cutsem E van, Labianca R, Hossfeld D, Bodoky G, Roth A, Aranda E, et al. Randomized phase III trial comparing infused irinotecan/ 5-fluorouracil/folinic acid versus 5-fluorouracil/folinic acid in stage III colon cancer patients (PETACC3). Proc Am Soc Clin Oncol 2005; 23:1090S.
19. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
20. Gramont de A, Boni C, Navarro M, Taberno J, Hickish T, Topham C, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and III colon cancer: efficacy results with a median follow-up of 4 years. Proc Am Soc Clin Oncol 2005;23:246S.
21. Punt CJA. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004;15:1453-9.
22. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
23. Kabbinavar F, Schulz J, McLeod M, Patel T, Hamm J, Hecht J, et al. Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression-free survival in first-line colorectal cancer patients who are not suitable candidates for first-line CPT-11 [abstract 3516]. Proc Am Soc Clin Oncol 2004;23:249S.
24. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract 2]. Proc Am Soc Clin Oncol 2005;23:1S.
25. Saltz LB, Lenz HJ, Hochster H, Wadler S, Hoff P, Kemeny N, et al. Randomized phase II trial of cetuximab/bevacizimab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer [abstract 3508]. Proc Am Soc Clin Oncol 2005;23:248S.
26. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, et al. Panitumumab (ABX-EGF) monotherapy in patients with metastatic colorectal cancer: an updated analysis [abstract 3511]. Proc Am Soc Clin Oncol 2004;23:247S.
27. Lenz HJ. Pharmacogenomics in colorectal cancer. Semin Oncol 2003;30(4 Suppl 15):47-53.
28. Cutsem E van, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-7.
29. Cassidy I, Twelves C, Cutsem E van, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 2002;13:566-75.
30. Punt CJA, Nortier JW, Bokkel Huinink WW ten, Falk S, Richel DJ, Maughan T, et al. Combination of irinotecan and capecitabine as first-line treatment in advanced colorectal cancer (ACC): results of a phase II trial [abstract 277]. Eur J Cancer 2003;1(Suppl 5):S85.
31. Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003;14:1378-82.
32. Grothey A, Jordan K, Kellner O, Constantine C, Dietrich G, Kroening H, et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial [abstract 295]. Eur J Cancer 2003;1(Suppl 5):S90.
33. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20: 3605-16.
34. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20: 3617-27.
35. Punt CJA. 'Hold the Mayo': solid facts or pulp fiction? Ann Oncol 2000;11:919-20.
36. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
37. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69.
38. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
39. Seymour M. Optimizing the use and sequencing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer: the UK MRC FOCUS (CR08) trial [abstract 5IN]. Ann Oncol 2004;15(Suppl 3):ii2.
40. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003;14(Suppl 2): ii13-6.
41. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases down-staged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-58.
42. Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004;15:1706-72.
43. Matar P, Rojo F, Cassia R, Moreno-Bueno G, di Cosimo S, Tabernero J, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004;10:6487-501.
44. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351: 337-45.
45. Saltz LB, Meropol NJ, Loehrer sr PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
46. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 3335-42.
47. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-9.